Breaking
European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
🇪🇺 EMA

Obesity Treatment

Page 1 • 1 item

Unlock insights into the global obesity treatment market. Track drug development, regulatory approvals, and investment trends for pharma BD professionals.

Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 2 Obesity Trial, Outperforming Current Market Leaders
NewsObesity and Metabolic HealthApr 29, 2026

Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 2 Obesity Trial, Outperforming Current Market Leaders

Survodutide delivered 39.2 lb average weight loss in 76-week trial, potentially superior to Wegovy and Zepbound in competitive obesity market.

Dr. Amina Farouk